MEMES: Against Table 2 in the “Choosing Wisely Canada” T3 & T4 toolkit

The "Choosing Wisely Canada" toolkit promoting limitation of Free T3 and Free T4 testing has been the food for some meme refutations. Choosing Wisely Canada. (n.d.). Toolkit: Less is More with T3 & T4. Retrieved December 30, 2018, from https://choosingwiselycanada.org/perspective/toolkit-t4-t3/ Recently, we've focused on their Table 2 which outlines situations they recommend NOT to order …

Continue reading MEMES: Against Table 2 in the “Choosing Wisely Canada” T3 & T4 toolkit

Ubiquitination: The glass ceiling of T4 monotherapy

UBIQUITINATION: This is the "Glass ceiling" of T4 monotherapy -- there is a biological limit on how much T3 you can get out of treatment with T4 thyroid hormone alone (Synthroid, levothyroxine). The enzyme responsible for the majority of our body's T4-T3 conversion is Deiodinase Type 2 (D2), and it does its job of conversion …

Continue reading Ubiquitination: The glass ceiling of T4 monotherapy

Our response to Choosing Wisely’s harmful Table 2

Choosing Wisely Canada, together with the Canadian Society for Endocrinology and Metabolism, have collaborated on a harmful toolkit to reduce Free T3 and Free T4 hormone testing in order to save money. As you can see in their Table 2 from page 9 of their toolkit, they want to prevent T3 and T4 testing in …

Continue reading Our response to Choosing Wisely’s harmful Table 2

Simpson’s paradox: Hoermann et al explain why T4-T3 therapy trials are faulty

Why have clinical trials of T3-T4 combination therapy failed to show significant benefit? Hoermann et al explain that the trials and the meta-analyses exhibit a fundamental problem with research methodology and a fundamental misunderstanding of thyroid hormone relationships that results in statistical errors. SOURCE Hoermann, R., Midgley, J. E. M., Larisch, R., & Dietrich, J. …

Continue reading Simpson’s paradox: Hoermann et al explain why T4-T3 therapy trials are faulty